In8bio News and Activities

In8bio is a company listed under the stock ticker INAB (US).

View the org chart displaying its 15 main executives

Most searched biographies at In8bio

• William Ho, Director, President and Chief Executive Officer
• Alan Roemer, Chairman of the Board
• Jeremy Graff, Director

Popular executive movements at In8bio

• Kate Rochlin, who was Chief Operating Officer, is promoted to President and Chief Operating Officer  (posted on February 9 2026).

Create your alert
to follow the executive moves at In8bio.

In8bio has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by In8bio

• IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients | IN8bio, Inc.
• Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform | IN8bio, Inc.
• IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development | IN8bio, Inc.
• IN8bio to Present at July Investor and Scientific Conferences | IN8bio, Inc.
• IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences | IN8bio, Inc.
• IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 | IN8bio, Inc.
• IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform | IN8bio, Inc.
• IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update | IN8bio, Inc.
• IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting | IN8bio, Inc.
• IN8bio to Present at May Investor and Scientific Conferences | IN8bio, Inc.
• View more press releases Close

Social media about In8bio

• In8bio on Wikipedia, Google News & Yahoo Finance
• In8bio on LinkedIn, X (Twitter) & YouTube